1. Show article details.

    Blackstone shares slip after $1.2 billion hotel deal

    MarketWatch – 5:54 PM ET 03/30/2015

    By Wallace Witkowski and Sue Chang, MarketWatch. Amgen (AMGN) shares decline as similar rival drug moves ahead. SAN FRANCISCO-- Blackstone Group LP (BX) shares slipped in the extended session Monday after the private capital manager said it bought three hotels for $1.2 billion.

  2. Show article details.

    Mylan stock drops after Abbott files to sell about one-third of its stake

    MarketWatch – 8:38 AM ET 03/30/2015

    Shares of Mylan NV (MYL) slumped 5% in premarket trade Monday, after the drug maker said it began a public offering of 35 million shares of its common stock held by Abbott Laboratories (ABT). That represents 32% of the 110 million Mylan shares owned by Abbott as of Feb. 27, according to FactSet. Mylan said Abbott is also granting the underwriters of the offering an option to buy an additional 5.25 million shares.

  3. Mylan's stock slumps 4.7% premarket after Abbott Labs files to sell part of stake

    MarketWatch – 8:31 AM ET 03/30/2015
  4. Show article details.

    Abbott Labs Files to Sell Nearly a Third of Its Mylan Stake

    DJ Business News – 8:23 AM ET 03/30/2015

    Abbott Laboratories (ABT) filed to offer nearly a third of its stake in Mylan NV (MYL) that it got from the recent sale of a portion of its generic-drugs business to the Netherlands-based drug maker. The companies in July said Mylan would buy Abbott's drug portfolio in developed overseas markets, in a $5.3 billion deal that would allow Mylan to benefit from a lower tax rate by organizing the new company in the Netherlands. Under a revised deal, Abbott received a stake of about 22% in the new Mylan.

  5. Show article details.

    Abbott's MitraClip® System Shown to Mend Hearts and Improve Lives in People in the United States

    PR Newswire – 2:00 PM ET 03/15/2015

    SAN DIEGO, March 15, 2015About three years ago, Betty Vaughn of Golden Valley, Minn., started to feel light-headed, fatigued and out of breath when she walked up and down the stairs. Vaughn's story shows how MitraClip can help people with a leaky heart valve feel better and resume their active lives.

  6. Show article details.

    BULLET: US PIPELINE: A total $8.75 billion of fresh..........

    Market News Intl Fixed Income Bullets – 8:17 AM ET 03/06/2015

    US PIPELINE: A total $8.75 billion of fresh investment-grade corporate bond supply priced (*) Thurs on the docket, contributing to a potential total this week of $62.65 billion, far exceeding the topmost estimate for $50 billion. - $550M *Alabama Power Co. (A1/A) 30Y T+107 BAML/BAR/GS/MIZ/MS $250M *Kimberly-Clark (KMB) de Mexico (A-/A) 10Y T+120 BAML/C 144A Reg S w/o Reg Rights $500M *Lam Research Corp (LRCX) (Baa1/BBB) 5Y T+120 BAML/JPM $500M *Lam Research Corp (LRCX) (Baa1/BBB) 10Y T+170 BAML/JPM $750M *Abbott Laboratories (ABT) (A2/A+) 5Y T+48 BAML/BAR/JPM/MS $750M *Abbott Laboratories (ABT) (A2/A+) 7Y T+68 BAML/BAR/JPM/MS $1.0B *Abbott Laboratories (ABT) (A2/A+) 10Y T+88 BAML/BAR/JPM/MS -more-

  7. Show article details.

    BULLET: US PIPELINE: A total $8.75 billion of fresh..........

    Market News Intl Fixed Income Bullets – 4:14 PM ET 03/05/2015

    US PIPELINE: A total $8.75 billion of fresh investment-grade corporate bond supply priced (*) today on the docket, contributing to a potential total this week of $62.65 billion, far exceeding the topmost estimate for $50 billion. - $550M *Alabama Power Co. (A1/A) 30Y T+107 BAML/BAR/GS/MIZ/MS $250M *Kimberly-Clark (KMB) de Mexico (A-/A) 10Y T+120 BAML/C 144A Reg S w/o Reg Rights $500M *Lam Research Corp (LRCX) (Baa1/BBB) 5Y T+120 BAML/JPM $500M *Lam Research Corp (LRCX) (Baa1/BBB) 10Y T+170 BAML/JPM $750M *Abbott Laboratories (ABT) (A2/A+) 5Y T+48 BAML/BAR/JPM/MS $750M *Abbott Laboratories (ABT) (A2/A+) 7Y T+68 BAML/BAR/JPM/MS $1.0B *Abbott Laboratories (ABT) (A2/A+) 10Y T+88 BAML/BAR/JPM/MS -more-

  8. Show article details.

    BULLET: US PIPELINE: A total $8.75 billion of fresh..........

    Market News Intl Fixed Income Bullets – 3:41 PM ET 03/05/2015

    US PIPELINE: A total $8.75 billion of fresh investment-grade corporate bond supply launched (#) or priced (*) today on the docket, contributing to a potential total this week of $62.65 billion, far exceeding the topmost estimate for $50 billion. - $550M *Alabama Power Co. (A1/A) 30Y T+107 BAML/BAR/GS/MIZ/MS $250M *Kimberly-Clark (KMB) de Mexico (A-/A) 10Y T+120 BAML/C 144A Reg S w/o Reg Rights $500M *Lam Research Corp (LRCX) (Baa1/BBB) 5Y T+120 BAML/JPM $500M *Lam Research Corp (LRCX) (Baa1/BBB) 10Y T+170 BAML/JPM $750M *Abbott Laboratories (ABT) (A2/A+) 5Y T+48 BAML/BAR/JPM/MS $750M *Abbott Laboratories (ABT) (A2/A+) 7Y T+68 BAML/BAR/JPM/MS $1.0B *Abbott Laboratories (ABT) (A2/A+) 10Y T+88 BAML/BAR/JPM/MS -more-

  9. Show article details.

    BULLET: US PIPELINE: Abbott Laboratories launched (#)........

    Market News Intl Fixed Income Bullets – 12:54 PM ET 03/05/2015

    US PIPELINE: Abbott Laboratories (ABT) launched (#) $2.5Bn 3-part: - $750M #Abbott Laboratories (ABT) (A2/A+) 5Y T+48 BAML/BAR/JPM/MS $750M #Abbott Laboratories (ABT) (A2/A+) 7Y T+68 BAML/BAR/JPM/MS $1.0B #Abbott Laboratories (ABT) (A2/A+) 10Y T+88 BAML/BAR/JPM/MS

  10. Show article details.

    Mylan still on the prowl for deals, perhaps one by end 2015

    Reuters – 7:23 PM ET 03/02/2015

    U.S. generic drug maker Mylan Inc (MYL) is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' (ABT) non-U.S. businesses just last week. Chief Executive Heather Bresch, on a call after the company posted fourth-quarter results on Monday, raised the prospect of another "material transaction" by the end of 2015.

  11. Show article details.

    Mylan Posts Higher Profit and Sales

    DJ Business News – 5:13 PM ET 03/02/2015

    Mylan Inc. (MYL) said fourth-quarter profit rose 5% as the drug company said it had an "exceptional" quarter. For 2015, the company expects earnings excluding items of $4 to $4.30 a share on revenue of $9.6 billion to $10.1 billion. Analysts polled by Thomson Reuters expected $4.16 and $9.81 billion.

  12. Show article details.

    Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

    PR Newswire – 12:30 PM ET 02/27/2015

    POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015Mylan N.V. and Mylan Inc. (MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Executive Chairman Robert J. Coury commented, "Today marks the beginning of the next exciting chapter of growth for Mylan.

  13. Show article details.

    Abbott Declares 365th Consecutive Quarterly Dividend

    PR Newswire – 10:36 AM ET 02/20/2015

    ABBOTT PARK, Ill., Feb. 20, 2015 The board of directors of Abbott today declared a quarterly common dividend of 24 cents per share. This marks the 365th consecutive quarterly dividend to be paid by Abbott since 1924.

  14. Show article details.

    Abbott to Present at Cowen and Company 35th Annual Health Care Conference

    PR Newswire – 9:00 AM ET 02/19/2015

    ABBOTT PARK, Ill., Feb. 19, 2015Abbott will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015. Scott White, senior vice president, international nutrition, and Brian Yoor, vice president, investor relations, will participate in the conference at 9 a.m. Central time.

  15. Show article details.

    Time for Boston Scientific shares to break out?

    MarketWatch – 12:33 PM ET 02/18/2015

    J&J lawsuit was' major overhang' on stock, analysts say. For much of the past decade, Boston Scientific Corp. (BSX) has struggled to keep up with the valuations of its rivals in the medical device-making business, its stock languishing in the teens and even single digits at times while competitors' shares fly at much higher levels. On Tuesday Boston Scientific (BSX) removed what many stock analysts say was a "major overhang" on its stock by reaching a $600 million settlement in a $7 billion lawsuit,...

  16. Show article details.

    Zoetis Profit Up 20%, 2015 Outlook Cut Slightly

    DJ Business News – 7:54 AM ET 02/11/2015

    Zoetis Inc. (ZTS) said its fourth-quarter earnings rose 20% on stronger revenue, though the animal-health company was the latest to have currency fluctuations weigh on growth. For 2015, the company lowered its revenue outlook slightly to $4.8 billion to $4.9 billion, from its previous estimate for $4.85 billion to $4.95 billion and affirmed its per-share earnings guidance. The updated outlook reflects foreign-exchange rates, the company's recent $255 million acquisition of...

  17. Show article details.

    RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.

    Business Wire – 5:00 AM ET 02/10/2015

    Rainbow Coral Corp.’s (RBCC) 3D bioprinting joint venture partner Nano3D Biosciences will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition.

  18. Show article details.

    RPT-INSIGHT-U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 7:00 AM ET 02/09/2015

    * Wave of inversion deals had many causes, experts say. * Earnings stripping, foreign profits seen as key. * Motivation for deals not clearly linked to tax rate. * Obama's budget last week proposed anti-inversion steps. By Kevin Drawbaugh.

  19. Show article details.

    U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 1:09 AM ET 02/09/2015

    When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate.

  20. Show article details.

    INSIGHT-U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 1:00 AM ET 02/09/2015

    * Wave of inversion deals had many causes, experts say. * Earnings stripping, foreign profits seen as key. * Motivation for deals not clearly linked to tax rate. * Obama's budget last week proposed anti-inversion steps. By Kevin Drawbaugh.

Page:

Today's and Upcoming Events

  • Apr
    13

    ABT ex-Dividend for $0.24 on 4/13/2015

    • Announce Date: 2/20/2015
    • Record Date: 4/15/2015
    • Pay Date: 5/15/2015
  • Apr
    15

    ABT to announce Q1 earnings Before Market (Unconfirmed)

  • Apr
    24

    Shareholders Meeting

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.